Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.49 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | PI4KA | P42356 | 2/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 6/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532632 | 0.86 | PI4KA (0.57) | PDPK1MAPK1CHEK1PAK1LMNA | |
| Adenine SCHEMBL28757891 | 0.80 | LMNA (0.73) | PDPK1MAPK1CHEK1PAK1LMNA | |
| SCHEMBL130821 | 0.80 | PDPK1 (0.49) | PDPK1MAPK1CHEK1PAK1LMNA | |
| Mercaptopurine Anhydrous SCHEMBL31379732 | 0.69 | LMNA (0.55) | PDPK1MAPK1CHEK1PAK1LMNA | |
| Purine SCHEMBL1705518 | 0.68 | ALDH1A1 (0.37) | PDPK1MAPK1CHEK1PAK1LMNA | |
| Mercaptopurine Anhydrous SCHEMBL29684795 | 0.66 | LMNA (0.57) | PDPK1MAPK1CHEK1PAK1LMNA | |
| SCHEMBL29692456 | 0.66 | LMNA (0.57) | PDPK1MAPK1CHEK1PAK1LMNA | |
| Mercaptopurine Anhydrous SCHEMBL8844 | 0.66 | LMNA (0.57) | PDPK1MAPK1CHEK1PAK1LMNA | |
| SCHEMBL336613 | 0.66 | MAPK1 (1.00) | PDPK1MAPK1CHEK1PAK1LMNA | |
| 2,6-Diaminopurine SCHEMBL2140437 | 0.66 | PDPK1 (0.74) | PDPK1LMNAPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442813-B2 | Process for producing dioxolane nucleoside analogues | SHIRE BIOCHEM INC. (CA) | 2008-10-28 | — | — | US | disclosed |
| US-20070197784-A1 | Process for producing dioxolane nucleoside analogues | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20050085638-A1 | Process for producing dioxolane nucleoside analogues | SHIRE BIOCHEM INC (CA) | 2005-04-21 | — | — | US | disclosed |
| EP-1467990-A1 | PROCESS FOR PRODUCING DIOXOLANE NUCLEOSIDE ANALOGUES | Shire Biochem Inc. (CA) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003062229-A1 | PROCESS FOR PRODUCING DIOXOLANE NUCLEOSIDE ANALOGUES | SHIRE BIOCHEM INC. (CA) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085638-A1 | Process for producing dioxolane nucleoside analogues | NUDT1, DPYD, DUT | PDPK1 648/4885MAPK1 902/4885CHEK1 2207/4885 |
| US-20070197784-A1 | Process for producing dioxolane nucleoside analogues | NUDT1, DPYD, DUT | PDPK1 648/4885MAPK1 902/4885CHEK1 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.